Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 07.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.
Unternehmen & Branche
| Name | IMPACT BIOMEDICAL INC. |
|---|---|
| Ticker | IBO |
| CIK | 0001834105 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 04529L106 |
|---|---|
| ISIN | US04529L1062 |
| Typ | Common Stock |
| Marktkapitalisierung | 8,1 Mio. USD |
| Beta | 3,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 32,000 | -11,838,000 | -0.38 | 17,405,000 | 12,609,000 |
| 2025-09-30 | 10-Q | 18,000 | -1,470,000 | -0.12 | 18,208,000 | -11,809,000 |
| 2025-06-30 | 10-Q | 7,000 | -14,346,000 | -1.18 | 19,060,000 | -10,341,000 |
| 2025-03-31 | 10-Q | -1,267,000 | -0.11 | 20,051,000 | 3,843,000 | |
| 2024-12-31 | 10-K | -24,708,000 | -2.30 | 20,290,000 | 4,259,000 | |
| 2024-09-30 | 10-Q | 4,247,000 | 0.06 | 46,695,000 | 31,348,000 | |
| 2024-06-30 | 10-Q | -889,000 | -0.09 | 44,116,000 | 23,373,000 | |
| 2024-03-31 | 10-Q | -962,000 | -0.10 | 44,356,000 | 24,260,000 | |
| 2023-12-31 | 10-K | -4,336,000 | -0.07 | 44,633,000 | 25,222,000 | |
| 2023-09-30 | 10-Q | -1,177,000 | -0.02 | 45,082,000 | 26,515,000 | |
| 2023-06-30 | 10-Q | -1,121,000 | -0.02 | 45,990,000 | 27,619,000 | |
| 2023-03-31 | 10-Q | -849,000 | -0.01 | |||
| 2022-12-31 | 10-K | 50,000 | -7,255,000 | -0.10 | 46,497,000 | 29,558,000 |
| 2022-09-30 | 10-Q | 50,000 | -2,236,000 | -0.03 | ||
| 2022-06-30 | 10-Q | 50,000 | -799,000 | 0.00 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | Macko Todd D | Officer, Chief Financial Officer | Open Market Sale | -43,400 | 0.56 | -24,369.10 | -72,9% | |
| 2026-03-25 | Macko Todd D | Officer, Chief Financial Officer | Open Market Sale | -1,600 | 0.60 | -961.28 | -2,9% | |
| 2026-03-23 | Grady Jason | Director | Open Market Sale | -50,000 | 0.65 | -32,505.00 | -97,3% | |
| 2025-05-27 | DSS, INC. | 10% Owner | Open Market Sale | -45,400 | 0.54 | -24,529.62 | -73,4% | |
| 2025-05-27 | DSS, INC. | 10% Owner | Open Market Sale | -45,400 | 0.54 | -24,529.62 | -73,4% | |
| 2025-05-22 | DSS, INC. | 10% Owner | Open Market Sale | -115,600 | 0.55 | -63,475.96 | -190,0% | |
| 2025-05-22 | DSS, INC. | 10% Owner | Open Market Sale | -115,600 | 0.55 | -63,475.96 | -190,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.